40
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Multiple primary tumours: challenges and approaches, a review

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          When in a patient more than one tumour in the same or a different organ is diagnosed, multiple primary tumours may be present. For epidemiological studies, different definitions of multiple primaries are used with the two main definitions coming from the project Surveillance Epidemiology and End Results and the International Association of Cancer Registries and International Agency for Research on Cancer. The differences in the two definitions have to be taken into consideration when reports on multiple primaries are analysed. In this review, the literature on multiple primaries is reviewed and summarised. Overall, the frequency of multiple primaries is reported in the range of 2–17%.

          Aetiological factors that may predispose patients to multiple primaries can be grouped into host related, lifestyle factors and environmental influences. Some of the most common cancer predisposition syndromes based on a clinical presentation are discussed and the relevant genetic evaluation and testing are characterised.

          Importantly, from a clinical standpoint, clinical situations when multiple primaries should be suspected and ruled out in a patient are discussed.

          Furthermore, general principles and possible treatment strategies for patients with synchronous and metachronous multiple primary tumours are highlighted.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          von Hippel-Lindau disease.

          von Hippel-Lindau disease is a heritable multisystem cancer syndrome that is associated with a germline mutation of the VHL tumour suppressor gene on the short arm of chromosome 3. This disorder is not rare (about one in 36000 livebirths) and is inherited as a highly penetrant autosomal dominant trait (ie, with a high individual risk of disease). Affected individuals are at risk of developing various benign and malignant tumours of the central nervous system, kidneys, adrenal glands, pancreas, and reproductive adnexal organs. Because of the complexities associated with management of the various types of tumours in this disease, treatment is multidisciplinary. We present an overview of the clinical aspects, management, and treatment options for von Hippel-Lindau disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

            An overview of cancer statistics and trends for selected cancers and all sites combined are given based on data from the Surveillance, Epidemiology, and End Results Program. Median age at diagnosis for all sites combined shows a 2-year increase from 1974 through 1978 to 1999 through 2003. Changes in cancer incidence rates from 1975 through 2003 are summarized by annual percent change for time periods determined by joinpoint regression analysis. After initial stability (1975-1979), incidence rates in women for all cancer sites combined increased from 1979 through 2003, although the rate of increase has recently slowed. For men, initial increases in all cancer sites combined (1975-1992) are followed by decreasing incidence rates (1992-1995) and stable trends from 1995 through 2003. Female thyroid cancer shows continued increasing incidence rates from 1981 through 2003. Blacks have the highest incidence and mortality rates for men and women for all cancer sites combined. Based on 2001 through 2003 data, the likelihood of developing cancer during one's lifetime is approximately one in two for men and one in three for women. Five-year relative survival for all stages combined (1996-2002) ranges from 16% for lung to 100% for prostate cancer patients. Cancer survival varies by stage of disease and race, with lower survival in blacks compared with whites. The risk of developing subsequent multiple primary cancers varies from 1% for an initial liver primary diagnosis to 16% for initial bladder cancer primaries. The impact on the future U.S. cancer burden is estimated based on the growing and aging U.S. population. The number of new cancer patients is expected to more than double from 1.36 million in 2000 to almost 3.0 million in 2050.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.

              In the current study, the authors attempted to describe the incidence, most common sites, and mortality of second primary malignancies among survivors of common cancers.
                Bookmark

                Author and article information

                Journal
                ESMO Open
                ESMO Open
                esmoopen
                esmoopen
                ESMO Open
                ESMO Open (BMA House, Tavistock Square, London, WC1H 9JR )
                2059-7029
                2017
                2 May 2017
                : 2
                : 2
                : e000172
                Affiliations
                [1 ] departmentDepartment of Oncology and Haematology , Kantonsspital St. Gallen , St.Gallen, Switzerland
                [2 ] departmentOncology , Inselspital and University of Berne , Berne, Switzerland
                [3 ] departmentMedizinische Genetik , Universittsspital Basel , Basel, Switzerland
                [4 ] departmentResearch Group Human Genomics, Zentrum für Lehre und Forschung, Labor 317/319, Department Biomedizin , University of Basel , Basel, Switzerland
                [5 ] Cancer Registry St. Gallen and Appenzell , St. Gallen, Switzerland
                Author notes
                [Correspondence to ] Aurelius Omlin, Department of Oncology and Haematology, Kantonsspital St.Gallen, Rorschacherstrasse 959007 St .Gallen, Switzerland; aurelius.omlin@ 123456kssg.ch
                Article
                esmoopen-2017-000172
                10.1136/esmoopen-2017-000172
                5519797
                28761745
                342b04cc-f340-404b-a301-54ba048e7f6d
                © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

                This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

                History
                : 30 January 2017
                : 6 March 2017
                : 17 March 2017
                Categories
                Review
                1506
                Custom metadata
                unlocked

                multiple primary cancer,second cancer,multiple primaries,secondary primary,epidemiology,genetic predisposition

                Comments

                Comment on this article